CRT Capital Cuts Valeant Pharma (VRX) to Fairly Valued
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
CRT Capital's Timothy Chiang downgraded shares of Valeant Pharmaceuticals (NYSE: VRX) from Buy to Fairly Valued Thursday afternoon.
The downgrade follows Q1 results from the company and news it will acquire AcneFree and certain assets from University Medical. Shares are down more than 9 percent at last check.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
The downgrade follows Q1 results from the company and news it will acquire AcneFree and certain assets from University Medical. Shares are down more than 9 percent at last check.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
DowngradesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
